Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insights, Epidemiology and Market Forecast-2028

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insights, Epidemiology and Market Forecast-2028

DelveInsight’s ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Chronic Inflammatory Demyelinating Polyneuropathy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chronic Inflammatory Demyelinating Polyneuropathy from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017-2028

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Disease Understanding

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. It is an acquired peripheral neuropathy due to an autoimmune attack of peripheral nerve myelin. Myelin is the main target of the condition, in which patients present with weakness, numbness, and sensory ataxia (symptoms of large myelinated fiber dysfunction).The disorder sometimes also called as chronic relapsing polyneuropathy. It is characterized by a symmetrical, motor predominant peripheral neuropathy that produces both distal and proximal weakness. Large-fiber abnormalities (weakness and ataxia) predominate, whereas small-fiber abnormalities (autonomic and pain) are less common. The disease often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by diagnosed Prevalent population, gender-specific diagnosed Prevalent population and clinical sub-type specific diagnosed Prevalent population and age- specific diagnosed prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the Prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy was estimated to be 45,127 [7MM] in 2018. United States accounts for the highest CIDP cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries France had the highest Prevalent patient population of Chronic Inflammatory Demyelinating Polyneuropathy, followed by United Kingdom.

Chronic Inflammatory Demyelinating Polyneuropathy Drug Chapters
This segment of the Chronic Inflammatory Demyelinating Polyneuropathy report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are many disease-modifying treatments for CIDP, but conventional therapies such as corticosteroids, Plasma Exchange (PE), and Intravenous immunoglobulin (IVIg) are considered as the first line therapies. These standard therapies have shown the improvement in 40% to 80% of patients and each of these therapies has been demonstrated to be effective in randomized, double-blind studies. However, a proportion of patients remain refractory to these therapies, individually or in combination. Corticosteroids has been in the therapeutic use for CIDP as of first reporting of cases. Mostly Prednisone and Dexamethasone is indicated among them; which has similar effects between patients with a progressive and relapsing course. Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) is the first and only subcutaneous immunoglobulin (SCIg) approved for the rare disease, and was developed to prevent relapse of neuromuscular disability and impairment, which are two common symptoms of patients with the CIDP condition. Hizentra offers patients a more convenient treatment option with proven efficacy and the flexibility and freedom to self-infuse at home. Detailed chapters for all of the marketed drugs along with other marketed therapies have been covered in the report.

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook
The Chronic Inflammatory Demyelinating Polyneuropathy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Eventhough the IVIg has the proven efficacy, the therapies are associated with high cost and frequent adverse effects. Current treatments are aimed at modulating the immune response, but as yet there is no clear evidence that these treatments also induce axonal regeneration. As non-responsiveness to treatment seems to be associated with a greater degree of axonal dysfunction, finding therapies aimed at protecting the axon and restoring axonal damage are needed.
According to DelveInsight, the global market of Chronic Inflammatory Demyelinating Polyneuropathy was estimated to be USD 473.5 million in 2018. The United States accounts for the largest market size of Chronic Inflammatory Demyelinating Polyneuropathy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The overall dynamics of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as GGS-CIDP (Teijin Pharma), NewGam (Octapharm) and HyQvia (Shire/Takeda). Out of all these emerging therapies, HyQvia (Shire/Takeda) is expected to have competitive advantage among the upcoming therapies, as it is once a month subcutaneous formulation. This drug is thus expected to have the highest market share, followed by GGS-CIDP (Teijin Pharma) and NewGam (Octapharm).

Chronic Inflammatory Demyelinating Polyneuropathy Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Chronic Inflammatory Demyelinating Polyneuropathy Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Chronic Inflammatory Demyelinating Polyneuropathy Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Chronic Inflammatory Demyelinating Polyneuropathy market.
• Organize sales and marketing efforts by identifying the best opportunities for Chronic Inflammatory Demyelinating Polyneuropathy market.
• To understand the future market competition in the Chronic Inflammatory Demyelinating Polyneuropathy market.